| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President of R&D | Director | President +4 more
2 companies
Vaishnaw Akshay serves as a President of R&D at SRRK and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 80 sells. Those positions are worth an estimated $35.5M at current prices.
Historically, Vaishnaw Akshay's trades have earned a middling insider score of 55/100 across 11 rated trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -12.8%.
The biggest single holding is SRRK (~$31.3M) as President of R&D. The recent filings there lean toward selling, a net 39,434 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16, 2026 | SRRK Scholar Rock Holding Corporation | President of R&D | Sell | 12,246 | $49.57 | $607,089.33 | -1.9% | +8.1% | - | |
| Jan 13, 2026 | SRRK Scholar Rock Holding Corp | President of R&D | Sell | 20,438 | $42.70 | $872,702.60 | -3.3% | +13.2% | - | |
| May 29, 2025 | SRRK Scholar Rock Holding Corp | President of R&D | Sell10b5-1 | 6,750 | $29.72 | $200,612.03 | -1.1% | +15.5% | +65.2% | |
| Aug 4, 2023 | ALNY Alnylam Pharmaceuticals, Inc. | President | Sell | 4,057 | $185.85 | $753,986.38 | -15.1% | -13.0% | +46.6% | |
| Apr 27, 2023 | ALNY Alnylam Pharmaceuticals, Inc. | President | Sell | 2,392 | $194.59 | $465,464.02 | -11.8% | -0.6% | -26.9% | |
| Feb 10, 2023 | ALNY Alnylam Pharmaceuticals, Inc. | President | Sale+OE | 38,044 | $215.97 | $8,216,323.70 | -71.8% | -4.3% | -21.0% | |
| Dec 23, 2021 | ALNY Alnylam Pharmaceuticals, Inc. | President, R&D | Sell | 2,879 | $190.93 | $549,698.04 | -20.4% | -16.5% | +22.4% | |
| Aug 9, 2021 | ALNY Alnylam Pharmaceuticals, Inc. | President, R&D | Sale+OE | 10,834 | $200.00 | $2,166,800.00 | -49.1% | -6.1% | +11.5% | |
| Jun 18, 2021 | ALNY Alnylam Pharmaceuticals, Inc. | President, R&D | Sale+OE | 14,708 | $175.00 | $2,573,900.00 | -56.7% | +7.5% | -22.5% | |
| Apr 21, 2021 | ALNY Alnylam Pharmaceuticals, Inc. | President, R&D | Sell | 6,438 | $137.36 | $884,326.97 | -31.3% | +33.2% | +22.7% |